Cuba needs syringes to distribute its vaccines in the final phase
- Cuba has the Soberana 2 and Abdala vaccines in their final phase and a major clinical trial with clinical vaccines is scheduled to take place in May. To do so, they need syringes and needles, and Cuba has called for international solidarity to help them buy on the market.
The Director of Science and Innovation of the Cuban Ministry of Health, Ilana Morales, has announced that in June the trials of the vaccines Soberana 2 and Abdala.El the Government of the island promised the world that it would open the patents and Soberana 2, this week, has begun to test them in Iran, in a phase 3 trial, with 24,000 patients.
These two vaccines are in their final phase and in May they want to do a large clinical trial in La Habana.Soberana 2 started the tests on March 4 in Havana and in the third phase involved 44,000 volunteers. Abdala, for its part, has received 48,000 volunteers in Santiago de Compostela, Granma and Guantánamo, among others. In August, more than half of the population is expected to be immunized, which would be reinforced by current clinical trials.
Morales has pointed out that Cuba has problems with this, as it has to buy the syringes to carry out its vaccination plan and as a page to do so. Cuba has called for international solidarity to help buy in the international market. Two million euros have been sent from Canada and campaigns are being carried out in Europe to purchase ten million euros.Se needles 25 million syringes to integrate the entire population of Cuba and it seems that the campaign has started with force.
The Sodepaz association has proposed to the organizations, parties and other organizations of the State Solidarity Movement with Cuba to participate in this campaign under the motto The Blockades kill your solidarity gives life. In the case of Euskal Herria, Sodepaz and the Euskadi-Cuba association are working to send one million syringes from the Spanish State.
Janssen farmazia multinazioanalak txertoaren ikerketa bertan behera uzteko erabakia hartu du, batzorde batek ondorioztatu ostean txertoak ez dituela giza immunoeskasiaren birusari aurre egiteko baldintzak betetzen.
Farmazia enpresa alemaniarrak hamar mila milioi euro irabazi ditu Covid-19aren aurkako txertoen patenteei esker. Hainbat ikerketak frogatu dute farmazeutiken lobbyek oztopatu dituztela patenteak askatzeko akordioak. BioNTechek sare sozialetako mezuak zentsuratu nahi izan ditu,... [+]
COVID-19 kasuek gora egin dute Europan eta 60 eta 79 urte artekoei eta gaitza larri pasatzeko arrisku handiagoa dutenei txertoaren laugarren dosia “berehala” jartzea gomendatu dute Sendagaien Europako Agentziak (EMA) eta Gaixotasunen Prebentziorako eta Kontrolerako... [+]
Erresuma Batuko Airfinity datu analizatzaileak aurreikusi du Europar Batasunak eta G7ko estatuek erositako milioika txerto dosi xahutuko direla erabili aurretik; ohartarazi dute banaketa arazoengatik izan litekeela. UNICEFek jakinarazi du herrialde pobretuek uko egin zietela 100... [+]
Nafarroako Osasun Publikoaren eta Lan Osasunaren Institutuaren azken txostenaren arabera, COVID-19ak eragindako heriotza kopurua oraingoaren bikoitza izango litzateke, haren kontrako txertoaren kanpaina martxan jarri ez balitz.
Many of the decisions of this pandemic need transparent, free and in-depth discussions. We should discuss infant vaccination against COVID-19, as the work on this Seminar on Innovation in Primary Care (SIAP) and the Spanish Network of Primary Care (REAP) have made clear.
The... [+]
Patenteetatik libre dagoen COVID-19aren aurkako txerto berri bat sortu du Texasko haurrentzako ospitaleko txertoen garapenerako zentroak (AEB). Indiak dagoeneko onartu du txerto hori erabiltzeko emergentziazko baimena eta haren sortzaileek espero dute laster Indonesian,... [+]
COVID-19ari dagokionez, abenduaren 22an hasi dute umeei zuzenduriko "hautuzko txertaketa" Ipar Euskal Herrian. Desadostasunak eta ulertu ezinak areagotzen ditu azken neurri honek.
Ayoade Alakija Afrikako Batasuneko presidentekideak salatu du omikron aldaera txertoen banaketa desorekatuaren ondorioz sortu dela. Bestalde, EMAk bosgarren txertoaren merkaturatzea onetsi du, “eraginkorra, kalitatezkoa eta segurua” dela baieztatuta; oraindik ez... [+]